While COVID-19 generally isn’t as dangerous to youngsters as to adults, some children do become severely ill or even die.
figuring out its approach. It aims to give tots an extra low dose — just one-tenth of the amount adults receive — but discovered during its trial that two shots didn’t seem quite strong enough for preschoolers. So researchers gave a third shot to more than 1,600 youngsters — from age 6 months to 4 years — during the winter surge of the omicron variant.
Preliminary data suggested the three-dose series is 80% effective in preventing symptomatic COVID-19, the companies said, but they cautioned the calculation is based on just 10 cases diagnosed among study participants by the end of April. The study rules state that at least 21 cases are needed to formally determine effectiveness, and Pfizer promised an update as soon as more data is available.
“We’ve learned in older children and adults that ... we really need three doses to get protection” against newer variants like omicron, Moss said. The FDA has tentatively planned for its expert panel to consider Moderna’s vaccine for older kids a day before taking up the question of shots for the littlest.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
COVID-19 vaccine for kids under 5: Pfizer says 3 small doses offer strong protectionPfizer says it plans to give the data to U.S. regulators later this week. The 18 million tots under 5 are the only group in the U.S. not yet eligible for COVID-19 vaccination.
Read more »
Three-dose Covid-19 vaccine produces strong immune response in young children, Pfizer and BioNTech sayThree child-size doses of the Pfizer/BioNTech Covid-19 vaccine appeared to be safe and showed a strong immune response in children ages 6 months to 5 years, the companies said Monday. The vaccine makers said they will finish submitting the trial data to the US Food and Drug Administration this week.
Read more »
Pfizer says its COVID-19 vaccine produces a strong immune response in kids under 5A third pediatric dose of the Pfizer-BioNTech COVID-19 vaccine in children 6 months to under 5 years of age prompted a strong immune response, with a safety profile that was similar to placebo, the companies said:
Read more »
Pfizer: 3 COVID-19 shots protect children under 5Pfizer says three small doses of its COVID-19 vaccine protect children under the age of 5 and that it plans to give the data to U.S. regulators later this week.
Read more »
U.S. FDA sets June meeting dates for Moderna, Pfizer small children COVID-19 vaccinesThe U.S. Food and Drug Administration set June 14-15 as the new meeting date to review Moderna Inc's emergency authorization request for its COVID-19 vaccine for children aged 6 months to 5 years and Pfizer Inc's vaccine for those aged 6 months through 4 years.
Read more »
Pfizer Says Their COVID-19 Vaccine For Kids Under 5 Is 80% Effective Against OmicronPfizer said in preliminary findings in a subset of a clinical trial indicate that 3 doses of the vaccine are 80% effective in preventing symptomatic infection.
Read more »